Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 514 results for "Tecfidera"

Biogen Idec Inc Earnings: Worth the Wait

Going into the release, there was worry that growth of Tecfidera, Biogen's oral multiple sclerosis drug, was slowing down, especially in the U.S., but that doesn't really seem to be as big of a problem as investors feared. There was one extra ... Motley Fool, 12 hours ago

Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity'

Credit Suisse on Thursday previewed Biogen Idec Inc (NASDAQ: BIIB) ahead of its fourth-quarter results. Biogen is rated as Outperform with a $400 price target. In the report, analyst Ravi Mehrota wrote, "Consensus numbers for Tecfidera, in ...
 Benzinga.com22 hours ago

Biogen Idec Earnngs

Biogen Idec is scheduled to announce its fourth quarter earnings before the market opens Wednesday. WHAT TO WATCH: -TECFIDERA SALES: Biogen's multiple sclerosis pill Tecfidera has quickly become the company's biggest-selling drug, with estimated ...
 Austin American Statesman3 days ago Tecfidera Sales Key for Biogen Idec — Earnings Preview  iMarketReports3 days ago

FDA updates label for Biogen MS pill due to Brain infection case

Federal regulators are updating the label for Biogen Idec Inc.'s hot-selling multiple sclerosis pill Tecfidera to describe the recent case of a patient taking the drug who developed a rare brain infection and died. In a safety alert posted Tuesday, ...
 Boston Globe2 months ago Biogen Idec Inc MS Drug Label Update To Include Fatal Brain Disease Risk  Bidness Etc2 months ago Why Tecfidera Drug Label Is Updated...  RTTNews.com2 months ago Biogen's Tecfidera Label Updated After Brain Infection Case  BusinessWeek2 months ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 2, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

FDA Issues Drug Safety Communication for Multiple Sclerosis Drug Tecfidera

The US Food and Drug Administration (FDA) issued a safety announcement about Biogen Idec's drug Tecfidera (dimethyl fumarate). The warning came November 25, after a 54 year old female patient with multiple sclerosis (MS) developed a rare brain ...
 HCPLive1 month ago FDA Warns of Rare Brain Infection Associated With MS Drug Tecfidera  FDA News1 month ago Serious Brain Infection Reported With Multiple Sclerosis Drug Use  Pharmacy Times2 months ago Tenth drug for relapsing remitting MS now available in the UK  Multiple Sclerosis Trust2 months ago

Forward Pharma Files Lawsuit Against Biogen Over Tecfidera Sales In Germany

Forward Pharma A/S (FWP: Quote) said Tuesday it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd (BIIB) in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 ...
 RTTNews.com2 months ago Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany  Vision Monday2 months ago Forward Pharma : Sues Biogen Idec Over Tecfidera(R) Sales in Germany  4 Traders2 months ago

U.S. Claims Data Show That Biogen Idec's Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients

BURLINGTON, Mass. , Nov. 24, 2014 /PRNewswire/ --Decision Resources Group finds that, according to U.S. patient-level claims data, Biogen Idec's Tecfidera, the third-to-market oral disease modifying therapy (DMT) for multiple sclerosis (MS), ...
 Crawford Financial Planning2 months ago

Shares Of Biogen Jump 7% After Hours On Earnings, Increased Sales Of Multiple Sclerosis Drug

Biogen increases in sales of its popular multiple sclerosis drug Tecfidera; net
 Tamar Securities12 hours ago

UPDATE: Barclays Capital Initiates Coverage On Biogen On Tecfidera Upside

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Biogen Idec Inc (NASDAQ: BIIB) with an Overweight rating and $425.00 price target. In the report, Barclays Capital noted, Biogen's Tecfidera still offers ...
 Benzinga.com3 weeks ago Barclays Initiates Coverage on Biogen Idec (BIIB)  Mideast Time3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less